Abiraterone and Increased Survival in Metastatic Prostate Cancer

• Published in: The New England journal of medicine Vol. 364; no. 21; pp. 1995 - 2005
• Main Authors: de Bono, Johann S, Logothetis, Christopher J, Molina, Arturo, Fizazi, Karim, North, Scott, Chu, Luis, Chi, Kim N, Jones, Robert J, Goodman, Oscar B, Saad, Fred, Staffurth, John N, Mainwaring, Paul, Harland, Stephen, Flaig, Thomas W, Hutson, Thomas E, Cheng, Tina, Patterson, Helen, Hainsworth, John D, Ryan, Charles J, Sternberg, Cora N, Ellard, Susan L, Fléchon, Aude, Saleh, Mansoor, Scholz, Mark, Efstathiou, Eleni, Zivi, Andrea, Bianchini, Diletta, Loriot, Yohann, Chieffo, Nicole, Kheoh, Thian, Haqq, Christopher M, Scher, Howard I
• Format: Journal Article
• Language: English
• Published: Waltham, MA Massachusetts Medical Society 26.05.2011
• Subjects: Acetic acid; Aged; Androgen Antagonists - adverse effects; Androgen Antagonists - therapeutic use; Androgens; Androgens - biosynthesis; Androstenes; Androstenols - adverse effects; Androstenols - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biosynthesis; Biotechnology; Cancer therapies; Castration; Chemotherapy; Disease Progression; Double-Blind Method; Fatigue - chemically induced; Fees & charges; General aspects; Gynecology. Andrology. Obstetrics; Humans; Hypertension; Hypokalemia; Kaplan-Meier Estimate; Laboratories; Male; Male genital diseases; Medical research; Medical sciences; Metastases; Middle Aged; Neoplasm Metastasis; Nephrology. Urinary tract diseases; Oncology; Pain; Patients; Prednisone; Prednisone - therapeutic use; Prostate cancer; Prostate-specific antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Steroid 17-alpha-Hydroxylase - antagonists & inhibitors; Survival; Survival Analysis; Treatment Outcome; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Urinary system disease; Prostate disease; Abiraterone; Antiandrogen; Antihormone; Malignant tumor; Metastasis; Survival; Medicine; Advanced stage; Metastatic; Male genital diseases; Prostate cancer; Cancer
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1014618

In this study, abiraterone acetate inhibited androgen synthesis and prolonged survival by 4 months among men with castration-resistant prostate cancer that had progressed with docetaxel chemotherapy. For the past 70 years, depleting or blocking the action of androgens has been the standard of care for men with advanced prostate cancer. 1 Androgen deprivation results in a decrease in the concentration of prostate-specific antigen (PSA) as well as tumor regression and relief of symptoms in most patients, but the response to treatment is not durable in patients with advanced cancer, and with time, PSA concentrations increase, indicating reactivated androgen-receptor signaling and a transition to a castration-resistant state that is invariably fatal. 2 Many endocrine therapies have been evaluated in these patients, but none have prolonged survival. 3 Three nonhormonal systemic . . .